Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH301:11

ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

5.0K
All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
5.0K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

3.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.2K
Acid-Catalyzed Ring-Opening of Epoxides02:24

Acid-Catalyzed Ring-Opening of Epoxides

7.2K
Epoxides that are three-membered ring systems are more reactive than other cyclic and acyclic ethers. The high reactivity of epoxides originates from the strain present in the ring. This ring strain acts as a driving force for epoxides to undergo ring-opening reactions either with halogen acids or weak nucleophiles in the presence of mild acid. The acid catalyst converts the epoxide oxygen, a poor leaving group, into an oxonium ion, a better leaving group, making the reaction feasible. The...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoxygenase (LOX) signaling in epilepsy: Pathophysiology and therapeutic prospects.

Neurobiology of disease·2026
Same author

QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models.

Molecular cancer therapeutics·2026
Same author

Novel EP2 Antagonist Attenuates Microgliosis and Memory Deficits in Pilocarpine-Induced Status Epilepticus Mice.

Journal of medicinal chemistry·2026
Same author

Topical difamilast for the treatment of mild-to-moderate atopic dermatitis.

Trends in pharmacological sciences·2026
Same author

Development of highly potent EP2 antagonists as novel anti-inflammatory neuroprotectants.

Bioorganic & medicinal chemistry·2026
Same author

Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.

Trends in pharmacological sciences·2026

Related Experiment Video

Updated: Apr 30, 2026

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
11:04

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

Published on: June 13, 2022

2.6K

Lead optimization studies of cinnamic amide EP2 antagonists.

Thota Ganesh1, Jianxiong Jiang, Myung-Soon Yang

  • 1Department of Pharmacology, School of Medicine, Emory University , 1510 Clifton Road, Atlanta, Georgia 30322, United States.

Journal of Medicinal Chemistry
|April 30, 2014
PubMed
Summary

New EP2 receptor antagonists show improved selectivity and solubility, offering potential for treating inflammatory diseases. These compounds could mitigate inflammation in central nervous system and peripheral conditions by blocking EP2 activation.

More Related Videos

Synthesis of Esters Via a Greener Steglich Esterification in Acetonitrile
06:52

Synthesis of Esters Via a Greener Steglich Esterification in Acetonitrile

Published on: October 30, 2018

35.9K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Related Experiment Videos

Last Updated: Apr 30, 2026

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
11:04

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

Published on: June 13, 2022

2.6K
Synthesis of Esters Via a Greener Steglich Esterification in Acetonitrile
06:52

Synthesis of Esters Via a Greener Steglich Esterification in Acetonitrile

Published on: October 30, 2018

35.9K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Area of Science:

  • Pharmacology
  • Immunology
  • Medicinal Chemistry

Background:

  • Prostanoid receptor EP2 (EP2) activation contributes to inflammation and disease pathology in the central nervous system and periphery.
  • Selective EP2 antagonists are being developed to counteract EP2-mediated inflammatory effects.
  • Previous cinnamic amide EP2 antagonists showed anti-inflammatory and neuroprotective properties but lacked optimal selectivity and solubility.

Purpose of the Study:

  • To develop novel EP2 antagonists with enhanced selectivity and improved pharmacokinetic properties.
  • To identify compounds with superior selectivity against related prostanoid receptors like DP1, EP4, and IP.
  • To create drug candidates with higher aqueous solubility for potential therapeutic applications.

Main Methods:

  • Synthesis and characterization of a new series of cinnamic amide-based EP2 antagonists.
  • Evaluation of receptor selectivity through in vitro assays against EP2, DP1, EP4, and IP receptors.
  • Assessment of aqueous solubility and plasma pharmacokinetics of the lead compounds.

Main Results:

  • Newly developed compounds exhibit up to 180-fold selectivity for EP2 over DP1.
  • Compounds demonstrate significantly improved aqueous solubility (up to 9-fold higher) compared to the previous lead.
  • Enhanced selectivity against EP4 and IP receptors was observed, with comparable plasma pharmacokinetics.
  • The optimized compounds are suitable for proof-of-concept studies in disease models involving detrimental EP2 activation.

Conclusions:

  • The novel cinnamic amide derivatives represent a significant advancement in EP2 antagonist development.
  • These compounds offer improved selectivity and solubility, making them promising candidates for further investigation.
  • The enhanced properties position these molecules as valuable tools for exploring EP2's role in inflammatory diseases.